Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes

Curr Oncol. 2022 Sep 25;29(10):6933-6946. doi: 10.3390/curroncol29100545.

Abstract

Myelodysplastic syndrome is one of the main hematological malignancies that threaten the health of the elderly. However, biomarkers which predict the progression and prognosis of MDS are still controversial and puzzling. FOXO1 gene plays an important role in a variety of intracellular functions, including tumor suppression and cellular immune regulation. However, there is no research report on the correlation between FOXO1 and the clinical features of MDS including immune environment. In this study, we observed that FOXO1 expression is associated with neutrophil count, blasts, chromosome and different MDS scoring systems. FOXO1 expression is closely related to MDS cell immune polarization, and the increase expression of FOXO1 is significantly related to the amplification of immune cell polarization ratio. In addition, FOXO1 expression is associated with progression-free survival and overall survival in MDS patients. Moreover, in a multivariate model FOXO1 low-expression was an independent predictor of poor survival in MDS. In summary, FOXO1 may play a candidate tumor suppressor in MDS, and FOXO1 is a useful independent prognostic predictor in MDS, and it may provide a candidate target therapy in future.

Keywords: FOXO1; immunity; myelodysplastic syndromes; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers
  • Forkhead Box Protein O1 / genetics
  • Humans
  • Myelodysplastic Syndromes* / genetics
  • Prognosis

Substances

  • Biomarkers
  • FOXO1 protein, human
  • Forkhead Box Protein O1

Grants and funding

This research was funded by the National Natural Science Foundation of China, grant number 81400091.